Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Tomizawa

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Cancer Medicine|April 6, 2023
Prevalence of pathogenic variants in cancer-predisposing genes in second cancer after childhood solid cancersMasanori Yoshida, Kazuhiko Nakabayashi, Wentao Yang, et al.
Journal of Clinical Immunology|February 2, 2021
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency DiseasesAkira Nishimura, Yuki Aoki, Yasuyoshi Ishiwata, et al.
Cancer Cell International|February 25, 2023
A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1Masashi Numata, Noriyasu Haginoya, Machiko Shiroishi, et al.
Blood Advances|November 2, 2018
Recurrent <i>CCND3</i> mutations in <i>MLL</i>-rearranged acute myeloid leukemiaHidemasa Matsuo, Kenichi Yoshida, Kazutaka Fukumura, et al.
International Journal of Hematology|October 14, 2017
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemiaYachiyo Kuwatsuka, Daisuke Tomizawa, Rika Kihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study GroupRomy E van Weelderen, Kim Klein, Christine J Harrison, et al.
Blood|May 10, 2011
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international studyEva A Coenen, Susana C Raimondi, Jochen Harbott, et al.
Blood|June 17, 2009
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective studyBrian V Balgobind, Susana C Raimondi, Jochen Harbott, et al.
Blood Advances|April 15, 2024
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemiaRomy E van Weelderen, Christine J Harrison, Kim Klein, et al.
Blood Advances|October 18, 2021
NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemiaMasanori Yoshida, Kazuhiko Nakabayashi, Wentao Yang, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Cancer Medicine|April 6, 2023
Prevalence of pathogenic variants in cancer-predisposing genes in second cancer after childhood solid cancersMasanori Yoshida, Kazuhiko Nakabayashi, Wentao Yang, et al.
Journal of Clinical Immunology|February 2, 2021
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency DiseasesAkira Nishimura, Yuki Aoki, Yasuyoshi Ishiwata, et al.
Cancer Cell International|February 25, 2023
A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1Masashi Numata, Noriyasu Haginoya, Machiko Shiroishi, et al.
Blood Advances|November 2, 2018
Recurrent <i>CCND3</i> mutations in <i>MLL</i>-rearranged acute myeloid leukemiaHidemasa Matsuo, Kenichi Yoshida, Kazutaka Fukumura, et al.
International Journal of Hematology|October 14, 2017
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemiaYachiyo Kuwatsuka, Daisuke Tomizawa, Rika Kihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study GroupRomy E van Weelderen, Kim Klein, Christine J Harrison, et al.
Blood|May 10, 2011
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international studyEva A Coenen, Susana C Raimondi, Jochen Harbott, et al.
Blood|June 17, 2009
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective studyBrian V Balgobind, Susana C Raimondi, Jochen Harbott, et al.
Blood Advances|April 15, 2024
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemiaRomy E van Weelderen, Christine J Harrison, Kim Klein, et al.
Blood Advances|October 18, 2021
NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemiaMasanori Yoshida, Kazuhiko Nakabayashi, Wentao Yang, et al.
Pageof 19